Abstract

Structure activity relationship (SAR) analyses of pharmacological data of compounds constitute an important part of the discovery process in the design of new drug candidates with improved pharmacological properties. In particular G-Protein Coupled Receptors (GPCRs) associated with the cAMP second messenger systems Gs and Gi have constituted one of the most widely used basis for pharmacological in vitro assays for assessing functional receptor effects. Such assays are based on Radio Immuno Assay (RIA) analysis to measure the cellular cAMP concentration as readout of receptor activation. It appears, however, to be a common practice to omit the use of cAMP standard curves to transform the measured signals (cpm or cps) into cAMP concentrations on which estima- tions of potencies (EC50 values) and efficacies (EMAX values) in Gs and Gi coupled receptor stimulation are based. Such practice may lead to significant errors as compounds mediating their effects via Gs coupled recep- tors may appear more potent and efficacious than they actually are. Contrary, compounds mediating their effects via Gi coupled receptors may appear less potent and effi- cacious than they are in reality. Potency rank orders will therefore change considerably, when estimations are based on incorrect calculation of the original experimental results. Thus, the only correct way to calculate effect data on which to base EMAX and EC50 estimations is to use cAMP concentrations derived from transformation of the measured signals (cpm or cps) using cAMP standard curves. The present work outlines the mathematical procedures by which such transformations are to be performed.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call